Board Member
Kay Abesamis is a seasoned pharmaceutical commercial leader with deep experience in both science and business. Kay has led global teams to successfully launch new cancer treatments, including the prostate cancer drug Talzenna®, and has helped shape strategies for other major therapies in blood disorders, biosimilars, and immunology. Known for a collaborative and diplomatic leadership style, Kay thrives in complex, fast-changing environments and builds strong partnerships across cultures and disciplines.
With a background in molecular biology and an MBA in marketing and finance, Kay brings a unique blend of scientific insight and commercial acumen. Kay has worked internationally – from the U.S. to Europe and Asia – and has contributed to projects ranging from contraceptive innovation to biotech licensing. Whether guiding product launches, evaluating new drug candidates, or managing alliances, Kay consistently drives impact through thoughtful strategy and clear execution.